Accessibility StatementSkip Navigation Conference Call and Webcast to Follow Corporate Contact:Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan MooreCollected Strategies[email protected] SOURCE Vanda Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will relea ...

Accessibility StatementSkip Navigation – Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT – SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRA ...

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potenti ...

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potenti ...

Core Insights - Palisade Bio, Inc. has successfully closed an underwritten public offering, raising approximately $138 million to support the Phase 2 clinical development of PALI-2108 for Ulcerative Colitis [1][2] Group 1: Offering Details - The offering consisted of 197,154,844 shares of common stock priced at $0.70 per share [3] - The offering was led by B Group Capital and Columbia Threadneedle Investments, with participation from several notable investors [1] Group 2: Use of Proceeds - Proceeds from the offering will be utilized to advance the clinical development program for PALI-2108, which targets significant unmet medical needs in inflammatory bowel disease (IBD) [2] Group 3: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]

Core Insights - Kiniksa Pharmaceuticals reported a strong commercial performance in Q2 2025, with ARCALYST net product revenue reaching $156.8 million, reflecting a 52% year-over-year growth [1][2][8] - The company has raised its 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from a previous range of $590 million to $605 million [2][13] - Kiniksa is advancing its clinical pipeline, with the initiation of the Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, expecting data in the second half of 2026 [4][15] Financial Performance - Total revenue for Q2 2025 was $156.8 million, compared to $108.6 million in Q2 2024 [8][22] - The net income for Q2 2025 was $17.8 million, a significant improvement from a net loss of $3.9 million in Q2 2024 [13][22] - Operating expenses for Q2 2025 totaled $136.6 million, up from $108.7 million in Q2 2024, with collaboration expenses increasing due to ARCALYST profitability [8][22] Product and Pipeline Updates - ARCALYST has been prescribed by over 3,475 prescribers for recurrent pericarditis, with an average treatment duration of approximately 30 months [7] - As of Q2 2025, about 15% of the target 14,000 multiple-recurrence patients are actively receiving ARCALYST treatment [7] - KPL-387 is in the dose-focusing portion of its Phase 2/3 trial, with plans for a pivotal trial to follow [4][15] Cash Position - Kiniksa's cash balance increased by $39.4 million in Q2 2025, reaching $307.8 million, with no debt reported [1][13][23] - The company expects to maintain a cash flow positive operating plan on an annual basis [13]

Financial Performance - As of March 31, 2025, the company had cash and cash equivalents and short-term deposits of $1,018 thousand, a decrease from $1,964 thousand as of March 31, 2024 [3] - Revenues for the three months ended March 31, 2025, totaled $586 thousand, reflecting a year-over-year increase driven by a higher number of contracts executed in the CDMO business [7] - R&D expenses for the same period amounted to $1,296 thousand, down from $1,568 thousand in 2024, primarily due to lower wages and reduced direct R&D expenses [7] - Marketing, general and administrative expenses were $500 thousand, slightly up from $484 thousand in the same period last year [7] - The net loss for the three months ended March 31, 2025, was $1,557 thousand, an improvement from a net loss of $2,159 thousand for the same period in 2024 [7] Business Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing innovative biological drug candidates for inflammation and immunology-related diseases [4] - The company operates two business units: one for in-house development of biological therapeutic products and another as a boutique CDMO providing various drug development services [4] - The CDMO unit began generating revenues in the second quarter of 2024, with full-year revenues for 2024 reported at $658 thousand [7]